Updated:
PathAI
PathAI builds AI-powered pathology software for biopharma and labs. Its AISight platform won FDA clearance for primary diagnosis in 2025.
PathAI
PathAI develops AI-driven pathology tools for drug development and laboratory diagnostics. The company's AISight platform is a cloud-native enterprise workflow system that integrates AI algorithms for histopathology use cases. PathAI serves biopharma partners for biomarker discovery and clinical trials, and anatomic pathology laboratories for primary diagnosis (per the firm, 2025). PathAI's strategy centers on three revenue streams: biopharma R&D collaborations, deployment of AISight to clinical labs, and a proprietary pathologist contributor network that generates training annotations. In June 2025, AISight Dx received FDA clearance for primary diagnosis (per the firm, June 2025). The firm partners with Labcorp and MedStar Health, among others. PathAI operates primarily in North America, with headquarters in Boston and additional offices in Princeton and Burlington. PathAI does not disclose funding, valuation, or AUM; it is a venture-backed company. In April 2026, PathAI partnered with MedStar Health to deploy AISight Dx (per the firm, April 2026). A pathologist contributor network provides interpretation services for R&D. The firm's team size is not publicly stated. PathAI's structural differentiator is its regulatory-first approach: it obtained FDA clearance for an AI pathology platform and an AI-assisted tool for MASH clinical trials (per the firm, June 2025). This regulatory posture creates a moat against pure software AI companies that lack clinical validation.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Additional offices
Princeton, NJ, United States · Burlington, MA, United States
Sector focus
Frequently asked questions
How does PathAI generate proprietary deal flow or revenue?
PathAI generates revenue through biopharma collaborations for biomarker discovery and drug development, deployment of its AISight platform to anatomic pathology laboratories, and its pathologist contributor network that provides annotation services for AI training (per the firm). The firm does not disclose revenue figures.
Does PathAI participate in fund commitments or only direct deals?
PathAI operates as a venture-backed company, not as an asset manager making fund commitments. Its capital is deployed into product development, clinical trials, and commercial partnerships.
What investment stages does PathAI typically target?
PathAI does not invest externally. It raises venture capital for its own operations; no public information on stage focus is available.
Which sectors does PathAI explicitly focus on?
PathAI focuses exclusively on pathology and artificial intelligence for healthcare. Its products serve biopharma and clinical laboratories.
How is PathAI related to any spinout or parent entity?
PathAI Diagnostics, the entity providing anatomic and digital pathology laboratory services, had select assets acquired by AmeriPath (a Quest Diagnostics company) on June 10, 2024 (per the firm). PathAI continues to operate its core technology and biopharma business.
Does PathAI maintain philanthropic structures?
No public information on philanthropic structures is available.
What is PathAI's known posture on co-investments alongside external GPs?
PathAI does not make co-investments alongside external GPs; it is an operating company not structured as an investment vehicle.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: